Search results for "Retreat"

showing 10 items of 90 documents

A decision analysis for periapical surgery : retrospective study

2018

Background Periapical surgery is now a reliable therapeutic procedure for the treatment of teeth with periapical lesions, particularly when orthograde retreatment is problematic. However, little information is available regarding treatment planning of cases referred for periapical surgery. Therefore, this study was conducted to analyze and evaluate the factors that affect the decision-making process for periapical surgery. Material and Methods This study retrospectively assessed clinical and radiographic data from patients undergoing periapical surgery. The factors involved in deciding to perform periapical surgery were classified into technical, biological, and combined factors. Results Ou…

0301 basic medicinebusiness.industryRadiographyResearchDentistryRetrospective cohort study030206 dentistrySurgical procedures:CIENCIAS MÉDICAS [UNESCO]03 medical and health sciences0302 clinical medicineCase selectionUNESCO::CIENCIAS MÉDICASMedicine030101 anatomy & morphologyOral SurgerybusinessRadiation treatment planningGeneral DentistryPeriapical surgeryEndodontic retreatmentDecision analysis
researchProduct

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

2017

0301 basic medicinemedicine.medical_specialtyhepacivirusHCV RASTreatment outcomeDrug ResistanceHCV genotypesDrug resistanceBiologyNS5A03 medical and health sciences0302 clinical medicineSecond linedrug resistance viral; humans; retreatment; treatment outcome; antiviral agents; hepacivirus; hepatitis c chronicInternal medicineDrug Resistance Viral; Humans; Retreatment; Treatment Outcome; Antiviral Agents; Hepacivirus; Hepatitis C ChronicDrug Resistance Viralantiviral agentsmedicineViralChronicNS5AhumansHepatologyhepatitis c chronicHepatitis CHepatitis C ChronicSettore MED/07 - Microbiologia e Microbiologia Clinicamedicine.diseaseHepatitis CVirologyHepatology HCV NS5A030104 developmental biologyHCVtreatment outcome030211 gastroenterology & hepatologyretreatmentdrug resistance viral
researchProduct

Corrigendum: Psychological Effects of a 1-Month Meditation Retreat on Experienced Meditators: The Role of Non-attachment

2016

Background: There are few studies devoted to assessing the impact of meditation-intensive retreats on the well-being, positive psychology, and personality of experienced meditators. We aimed to assess whether a 1-month Vipassana retreat: (a) would increase mindfulness and well-being; (b) would increase prosocial personality traits; and (c) whether psychological changes would be mediated and/or moderated by non-attachment. Method: A controlled, non-randomized, pre-post-intervention trial was used. The intervention group was a convenience sample (n = 19) of experienced meditators who participated in a 1-month Vipassana meditation retreat. The control group (n = 19) comprised matched experienc…

050103 clinical psychologyMindfulnessmeditationmedia_common.quotation_subjectpositive psychology050105 experimental psychologyVipassanawellbeingPositive psychologyretreatPsychologyPersonality0501 psychology and cognitive sciencesMeditationBig Five personality traitsGeneral PsychologyOriginal Researchmedia_commonWellbeing05 social sciencesCooperativenessCorrectionModerationMeditacióMeditationpersonalityTemperamentPositive psychologyPsychologyRetreatClinical psychologyPersonality
researchProduct

Health coverage for a retreating army: a Medical Captain’s action during the Maestrazgo campaign (April-July 1938).

2012

espanolAntecedentes y objetivos: Tras la entrada definitiva de las tropas del general Franco en la ciudad de Teruel en febrero de 1938 se inicio la retirada progresiva del Ejercito de Maniobra de la republica. El rapido avance de las fuerzas nacionales hacia el Mediterraneo marco las caracteristicas de la cobertura sanitaria militar. El objetivo de este trabajo es realizar una aproximacion a la Sanidad del Ejercito republicano durante su retirada por el Maestrazgo castellonense, que tuvo lugar entre abril y julio de 1938 en el contexto de la Guerra Civil Espanola (1936-1939). Material y metodos: Hemos utilizado una fuente de gran valor historico, como es el testimonio oral de un Capitan Med…

5506.17 Historia de la MedicinaMilitary Health CareGeneral EngineeringSanidad militarMaestrazgo Battle5503.02 Historia RegionalBatalla del MaestrazgoSpanish Civil WarGuerra Civil españolaGeneral Earth and Planetary SciencesRetreating army5103.05 GuerraEjército en retiradaGeneral Environmental ScienceSanidad Militar
researchProduct

Aneurysm clipping following endovascular coil embolization: A report of two cases

2009

Abstract BACKGROUND: Treatment of intracranial aneurysms by Guglielmi detachable coil (GDC) embolization is a useful therapeutic alternative to surgery. This procedure is attractive as a minimally invasive approach to treat cerebral aneurysms; however, is not devoid of complications or failure and retreatment, with either a surgical or endovascular technique, may often be required. CASE REPORTS: Two cases are presented in which surgery was required after coil embolization. In one case, surgical treatment was performed one month later because of regrowth and subsequent bleeding of the aneurysm. In the second case, surgical treatment was carried out six months later because of recanalization …

AdolescentSettore MED/27 - Neurochirurgiaaneurysm rest; cerebral aneurysm; guglielmi detachable coils; retreatmentIntracranial AneurysmMiddle AgedEmbolization Therapeuticcerebral aneurysmguglielmi detachable coilsCerebral aneurysm coli embolizzation subharachnoid hemorrhageCerebral aneurysm clippingHumansFemaleaneurysm restretreatment
researchProduct

Goldmann Tonometry After Hyperopic Laser In Situ Keratomileusis

2004

PURPOSE To identify differences in applanation tonometry between retreated and nonretreated eyes (primary LASIK eyes) 6 months after hyperopic laser in situ keratomileusis. METHODS In a prospective study 100 eyes (100 patients) underwent conventional hyperopic laser in situ keratomileusis under a 160-microm flap. Central Goldmann applanation tonometry was determined before and 6 months after surgery in 78 (78%) primary LASIK eyes and before surgery and 6 months after the retreatment date in 22 (22%) retreated eyes. RESULTS Preoperative mean tonometry was 14.96 +/- 1.96 mm Hg and 15.30 +/- 1.95 mm Hg in primary LASIK and retreated eyes, respectively. Six months after surgery it was 12.99 +/-…

AdultApplanation tonometrymedicine.medical_specialtyIntraocular pressureTime Factorsgenetic structuresmedicine.medical_treatmentKeratomileusis Laser In SitueducationKeratomileusisGoldmann applanation tonometryTonometry OcularmedicineHumansPostoperative PeriodProspective StudiesIntraocular Pressurebusiness.industrySignificant differenceLASIKhumanitieseye diseasesSurgeryGoldmann tonometryOphthalmologyHyperopiaTreatment OutcomeRetreatmentsense organsbusinessCornea
researchProduct

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractor…

2018

AbstractPurpose:Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor.Patients and Methods:Patients age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective were enrolled (NCT01703481). Parts 2 to 4 employed molecular screening for activating FGFR genomic alterations. In patients with such alterations, two selected doses/schedules identified during part 1 dose-escalation [9 mg once daily and 10 mg intermittently (7 days on/7 days off), as previously published (Tabernero JCO 2015;33:3401-8)] were tested.Results:The study included 187 patients. The most common treatment-related adverse events were…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyAdministration OralAntineoplastic AgentsDrug resistanceGastroenterologyYoung Adult03 medical and health sciencesHyperphosphatemia0302 clinical medicineRefractoryErdafitinibNeoplasmsQuinoxalinesInternal medicinemedicineHumansNeoplasmDosingAdverse effectProtein Kinase InhibitorsAgedNeoplasm StagingAged 80 and overbusiness.industryGenetic VariationMiddle AgedPrognosismedicine.diseaseReceptors Fibroblast Growth FactorTreatment Outcome030104 developmental biologyOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisRetreatmentPyrazolesFemalebusinessClinical Cancer Research
researchProduct

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multi…

2015

This phase 1/2 study was the first to evaluate the safety and efficacy of the cyclin-dependent kinase (CDK) 4/6-specific inhibitor palbociclib (PD-0332991) in sequential combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. The recommended phase 2 dose was palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (intravenous) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 (early G1 arrest) and days 15 and 18 (cell cycle resumed). Dose-limiting toxicities were primarily cytopenias; most other treatment-related adverse events were grade≤3. At a bortezomib dose lower than that in other combina…

AdultMaleCancer ResearchCombination therapyPyridinesKaplan-Meier EstimatePalbociclibPharmacologyDexamethasoneDrug Administration SchedulePiperazinesBortezomibRecurrenceCyclin-dependent kinaseAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineMultiple myelomaDexamethasoneAgedNeoplasm StagingAged 80 and overbiologybusiness.industryBortezomibCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HematologyMiddle AgedCell cyclemedicine.diseaseTreatment OutcomeOncologyDrug Resistance NeoplasmPharmacodynamicsRetreatmentbiology.proteinFemaleDrug MonitoringMultiple Myelomabusinessmedicine.drugLeukemia & Lymphoma
researchProduct

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorecta…

2009

BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5-fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. METHODS: The authors included 48 heavily pretreated patients (colon:rectum, 33:15; men:women, 23:25; median age, 63 years; range, 27-79 years) whose disease had progressed during or within an oxaliplatin-based first-line chemotherapy, an irinotecan-based second-line regimen, and a third-line treatment with cetuximab plus weekly irinotecan. Bevacizumab was given at a dose of 5 mg/kg. 5-FU/folinic acid was administered according to the de Gramont schedule. RESULTS: The respo…

AdultMaleCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerSettore MED/06 - Oncologia MedicaLeucovorinCetuximabAntibodies Monoclonal HumanizedGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCetuximabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseSurgeryOxaliplatinIrinotecanBevacizumabRegimenBevacizumabcolorectal cancerOncologyDrug Resistance NeoplasmRetreatmentFemaleFluorouracilbusinessBevacizumab; Colorectal cancer; cancer combination chemotherapyColorectal Neoplasmsmedicine.drug
researchProduct

Intrauterine therapy of goitrous hypothyroidism in a boy with a new compound heterozygous mutation (Y453D and C800R) in the thyroid peroxidase gene. …

2004

We report the results of intrauterine L-thyroxine therapy, and the long-term follow-up in a fetus who presented at 32 weeks' gestation with goitrous hypothyroidism, hyperextension of the neck, and polyhydramnios. Spontaneous delivery was possible and hypothyroidism improved. Molecular analysis revealed a new compound heterozygous mutation (Y453D/C800R) in the TPO gene.

AdultMalePolyhydramniosendocrine systemmedicine.medical_specialtyPolyhydramniosGoiterendocrine system diseasesCompound heterozygosityIodide PeroxidaseInjectionsLoss of heterozygosityHypothyroidismPregnancyInternal medicineCongenital HypothyroidismMedicineHumansThrombopoietinFetusFetal Therapiesbusiness.industryGoiterObstetrics and Gynecologymedicine.diseaseCongenital hypothyroidismFetal DiseasesThyroxineEndocrinologyRetreatmentGestationFemalebusinessFollow-Up StudiesAmerican journal of obstetrics and gynecology
researchProduct